U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BACITRACIN

Approved Use

Uses first aid to help prevent infection in: •minor cuts •scrapes •burns

Launch Date

1948
Curative
CORTISPORIN

Approved Use

For the treatment of corticosteroid-responsice dermatoses with secondary infection.

Launch Date

1957
Curative
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

Launch Date

1968
PubMed

PubMed

TitleDatePubMed
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo.
1948 Mar
Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene.
1950 Feb
Detection by HPLC-ICP of metallothionein in serum of an epileptic child with valproate-associated hepatotoxicity.
1992 Dec
Differential dephosphorylation of the insulin receptor and its 160-kDa substrate (pp160) in rat adipocytes.
1992 Jul 15
Intestinal damage induced by zinc deficiency is associated with enhanced CuZn superoxide dismutase activity in rats: effect of dexamethasone or thyroxine treatment.
1999 May
Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene.
1999 Sep 10
The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.
2000 Feb 15
Regulation of metallothionein gene expression by oxidative stress and metal ions.
2000 Jan 1
Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections.
2000 May
Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein.
2000 Nov 28
cDNA array analysis identifies thymic LCK as upregulated in moderate murine zinc deficiency before T-lymphocyte population changes.
2001 Dec
Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT.
2001 Feb 28
Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc.
2001 Mar
p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis.
2001 May 15
Loss of vesicular zinc and appearance of perikaryal zinc after seizures induced by pilocarpine.
2001 May 25
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.
2001 Nov
Influence of dietary zinc deficiency during development on hepatic CYP2C11, CYP2C12, CYP3A2, CYP3A9, and CYP3A18 expression in postpubertal male rats.
2001 Nov 1
Modulation of intestinal gene expression by dietary zinc status: effectiveness of cDNA arrays for expression profiling of a single nutrient deficiency.
2001 Nov 20
Metallothionein is required for zinc-induced expression of the macrophage colony stimulating factor gene.
2002
Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle.
2002 Dec 13
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.
2002 Jan 15
Partitioning of accumulated trace metals in the talitrid amphipod crustacean Orchestia gammarellus: a cautionary tale on the use of metallothionein-like proteins as biomarkers.
2002 Jun
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents.
2002 Nov
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation.
2002 Oct
Effect of chromium on apolipoprotein A-I expression in HepG2 cells.
2003 Apr
The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice.
2003 Aug 29
Effects of zinc occupancy on human O6-alkylguanine-DNA alkyltransferase.
2003 Feb 4
Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice.
2003 Jan
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites.
2003 Jun
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase.
2003 May 2
Zinc modulates PPARgamma signaling and activation of porcine endothelial cells.
2003 Oct
Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate.
2003 Oct 3
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration: Topical
The MIC value was 32 mg/L for Staphylococcus aureus wild type strain after 48h incubation at 37°C.
Substance Class Mixture
Created
by admin
on Sat Dec 16 17:50:15 GMT 2023
Edited
by admin
on Sat Dec 16 17:50:15 GMT 2023
Record UNII
58H6RWO52I
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
Bacitracin
EP   HSDB   INN   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
BACITRACIN [USP IMPURITY]
Common Name English
TOPITRACIN
Common Name English
NSC-755905
Code English
LANABIOTIC COMPONENT BACITRACIN
Common Name English
BACITRACIN [WHO-IP]
Common Name English
PENITRACIN
Common Name English
BACITRACIN [EP MONOGRAPH]
Common Name English
MYCITRACIN COMPONENT BACITRACIN
Common Name English
FORTRACIN
Common Name English
BACITRACIN [JAN]
Common Name English
BACITRACIN [VANDF]
Common Name English
BACIIM
Brand Name English
PARENTRACIN
Common Name English
BACITRACIN [USP MONOGRAPH]
Common Name English
BACIGUENT
Brand Name English
BACI-RX
Brand Name English
BACITRACIN [ORANGE BOOK]
Common Name English
BACILLIQUIN
Common Name English
Bacitracin [WHO-DD]
Common Name English
BACITRACIN [HSDB]
Common Name English
BACITRACINUM [WHO-IP LATIN]
Common Name English
BACITRACIN COMPONENT OF MYCITRACIN
Common Name English
ZUTRACIN
Common Name English
BACITRACIN COMPONENT OF LANABIOTIC
Common Name English
TROPITRACIN
Common Name English
bacitracin [INN]
Common Name English
BACITRACIN(NON-INJECTABLE) [WHO-IP]
Common Name English
BACITRACIN [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 1284
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
WHO-VATC QR02AB04
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
WHO-ATC J01XX10
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
CFR 21 CFR 333.120
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
CFR 21 CFR 524.155
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
WHO-ATC R02AB04
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
CFR 21 CFR 556.70
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
EPA PESTICIDE CODE 6302
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
CFR 21 CFR 333.110
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
CFR 21 CFR 524.154
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
CFR 21 CFR 520.154
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
WHO-ATC D06AX05
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
WHO-VATC QJ01XX10
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
WHO-VATC QD06AX05
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
WHO-VATC QA07AA93
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
Code System Code Type Description
WIKIPEDIA
BACITRACIN
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-786-2
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
NSC
755905
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
EVMPD
SUB00652MIG
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
RXCUI
1291
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
BACITRACIN
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures.
DRUG BANK
DB00626
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
FDA UNII
58H6RWO52I
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
NCI_THESAURUS
C295
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
INN
1167
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
MERCK INDEX
m2197
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY Merck Index
NDF-RT
N0000008479
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY Decreased Cell Wall Synthesis & Repair [PE]
LACTMED
Bacitracin
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
DAILYMED
58H6RWO52I
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
MESH
D001414
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
CAS
1405-87-4
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200558
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
DRUG CENTRAL
281
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
CHEBI
28669
Created by admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
MIC
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.40.pdf
Definition References